Department of Pharmacy, Duke University Hospital, Durham, North Carolina, USA.
Department of Medicine, Division of Nephrology, Duke University School of Medicine, Durham, North Carolina, USA.
Transpl Infect Dis. 2024 Oct;26(5):e14364. doi: 10.1111/tid.14364. Epub 2024 Aug 26.
In kidney transplantation, concerns have been raised regarding increased incidence of viral opportunistic infections in hepatitis C virus (HCV) nucleic acid test (NAT)-negative (-) recipients who received HCV NAT-positive (+) donor kidneys, specifically BK polyomavirus (BKPyV), cytomegalovirus (CMV), and Epstein-Barr virus (EBV). The purpose of this study was to determine the incidence of these three viral opportunistic infections in HCV NAT- recipients who have undergone kidney transplantation with HCV NAT+ donor kidneys at our institution.
This was an Institutional Review Board-approved, single-center, retrospective case-control study of HCV NAT- kidney transplant recipients with HCV NAT+ donors from 2018 to 2021. The primary outcome was the cumulative incidence of viral infections of BKPyV, CMV, and/or EBV within 1 year following kidney transplantation.
A total of 231 patients were included, 77 in the exposed (donor HCV NAT+) group and 154 in the control (donor HCV NAT-) group. The adjusted cumulative incidence of viremia within 1 year did not statistically differ between groups (77% exposed group versus 66% for the control group, hazard ratio 1.34, 95% confidence interval 0.95-1.89). In addition, no statistically significant differences were observed for secondary outcomes with the exception of CMV viremia (62% exposed versus 49% control, p = 0.021). However, there were more patients in the exposed group at high risk for CMV viremia based on serostatus (CMV Donor+/Recipient-, D+/R-).
Among patients who received HCV NAT+ donor kidneys, no clear association was observed between exposure to HCV NAT+ donor kidneys and viral infections of BKPyV, CMV, or EBV.
在肾移植中,人们对 HCV 核酸检测(NAT)阴性(-)受者接受 HCV NAT 阳性(+)供体肾脏后,病毒机会性感染发生率增加表示担忧,特别是 BK 多瘤病毒(BKPyV)、巨细胞病毒(CMV)和 EBV。本研究旨在确定本机构接受 HCV NAT+供体肾脏进行肾移植的 HCV NAT-受者中这三种病毒机会性感染的发生率。
这是一项经机构审查委员会批准的、单中心、回顾性病例对照研究,纳入 2018 年至 2021 年 HCV NAT-肾移植受者,供体为 HCV NAT+。主要结局是肾移植后 1 年内 BKPyV、CMV 和/或 EBV 病毒感染的累积发生率。
共纳入 231 例患者,暴露组(供体 HCV NAT+)77 例,对照组(供体 HCV NAT-)154 例。调整后 1 年内病毒血症的累积发生率在两组间无统计学差异(暴露组 77% vs. 对照组 66%,风险比 1.34,95%置信区间 0.95-1.89)。此外,除 CMV 病毒血症外(暴露组 62% vs. 对照组 49%,p=0.021),其他次要结局均无统计学差异。然而,基于血清学状态(CMV 供体+/受体-,D+/R-),暴露组中 CMV 病毒血症高危患者更多。
在接受 HCV NAT+供体肾脏的患者中,暴露于 HCV NAT+供体肾脏与 BKPyV、CMV 或 EBV 病毒感染之间未观察到明确关联。